Inflammatory bowel disease (IBD) – encompassing Crohn’s disease and ulcerative colitis – is a group of chronic conditions in which the immune system mounts a sustained, dysregulated inflammatory response against the gastrointestinal tract. The result is recurring episodes of abdominal pain, diarrhea, bleeding, and systemic inflammation that significantly impair quality of life.
This regenerative approach is an area of active and growing research. In particular, mesenchymal stem cells (MSCs) – valued for their immunomodulatory and anti-inflammatory properties – have emerged as a promising therapeutic avenue for patients with refractory IBD who have not responded adequately to conventional treatments.
hat Are the Symptoms of Inflammatory Bowel Disease
Understanding what drives symptoms is important context for understanding why stem cell approaches are being investigated.
Crohn’s disease can affect any part of the gastrointestinal tract from mouth to anus and is characterized by transmural (full-thickness) inflammation that can lead to strictures, fistulas, and abscesses. Common symptoms include:
- Abdominal cramping and pain
- Chronic diarrhea, sometimes with blood
- Unintended weight loss and nutritional deficiencies
- Fatigue and low energy
- Perianal complications including fistulas
Ulcerative colitis affects only the colon and rectum, typically involving continuous mucosal inflammation. Symptoms include:
- Bloody diarrhea
- Urgency and tenesmus (feeling of incomplete bowel emptying)
- Abdominal cramping
- Anemia from blood loss
Both conditions involve episodes of active disease (flares) alternating with periods of remission. The intensity and frequency of flares vary widely between patients (Ordás et al., Lancet, 201260150-0)).
How to Treat Inflammatory Bowel Disease: Current Approaches
Standard IBD management has expanded significantly with the development of biologic agents. Current treatment options include:
- Aminosalicylates (5-ASA): First-line for mild-to-moderate ulcerative colitis
- Corticosteroids: For managing active flares
- Immunomodulators: Azathioprine, 6-mercaptopurine, methotrexate for maintenance
- Biologics: Anti-TNF agents (infliximab, adalimumab), anti-integrin therapies (vedolizumab), IL-12/23 inhibitors (ustekinumab), JAK inhibitors
- Surgery: Bowel resection or colectomy for medically refractory disease
Despite this range of options, a meaningful proportion of IBD patients do not achieve or maintain remission with available therapies – and some develop immune tolerance to biologics over time. For these patients with refractory IBD, new therapeutic strategies are needed.
How Stem Cell Therapy Works for IBD
Two main stem cell approaches have been investigated for IBD:
1. Mesenchymal Stem Cell (MSC) Therapy
MSCs – derived from bone marrow, adipose tissue, or umbilical cord – are infused intravenously or injected locally (particularly for fistulizing Crohn’s disease). Their mechanism of action in IBD centers on immune regulation:
- MSCs secrete TGF-β, IL-10, and prostaglandin E2, which suppress excessive T-cell activation and reduce the pro-inflammatory cytokines (TNF-α, IL-6, IFN-γ) driving intestinal inflammation
- They promote expansion of regulatory T cells (Tregs), which help maintain immune tolerance in the gut
- Local injection for perianal fistulas in Crohn’s disease allows targeted delivery of anti-inflammatory signals directly to the affected tissue
2. Hematopoietic Stem Cell Transplantation (HSCT)
Autologous HSCT – where a patient’s own stem cells are collected, the immune system is ablated with chemotherapy, and the stem cells are re-infused – has been used in severe, treatment-resistant Crohn’s disease. This approach essentially “reboots” the immune system. It is reserved for highly selected refractory cases due to its intensity and risk profile.
The Clinical Evidence
The clinical evidence for MSC therapy in IBD has grown substantially over the past decade.
A Phase 2 trial examining allogeneic MSC infusion in patients with luminal Crohn’s disease refractory to biologic therapy found clinically meaningful improvements in disease activity scores compared to baseline, supporting the safety and potential efficacy of MSC therapy in this difficult-to-treat population (Forbes et al., Clin Gastroenterol Hepatol. 2014).
A series of seven patients with refractory IBD (both Crohn’s disease and ulcerative colitis) who received allogeneic MSC transplantation demonstrated marked reductions in disease activity scores and inflammatory markers, with evidence of intestinal healing at follow-up (Liang et al., Gut, 2012).
The most significant clinical milestone came with the Phase 3 ADMIRE-CD trial, which evaluated darvadstrocel (Cx601) – expanded allogeneic adipose-derived MSCs – for complex perianal fistulas in Crohn’s disease. The trial showed that 50% of patients receiving MSC treatment achieved combined remission (fistula closure) at 24 weeks, compared to 34% with placebo – a statistically significant result that led to regulatory approval of this product in Europe (Panés et al., Lancet, 201631203-X)).
What Patients Should Know Before Exploring This Treatment
Stem cell therapy for IBD is not a first-line treatment. It is currently most supported for:
- Refractory Crohn’s disease (particularly fistulizing disease) after failure of at least one biologic agent
- Selected cases where conventional therapies have been exhausted
- Patients enrolled in clinical trials or treated at centers with clinical expertise in MSC delivery
For patients with standard IBD who are responding to conventional treatment, established therapies remain the appropriate management approach. Regenerative medicine in IBD is a complement to – not a replacement for – established gastroenterological care.
Frequently Asked Questions
Is stem cell therapy available for Crohn’s disease?
Yes – particularly for perianal fistulizing Crohn’s disease. MSC-based therapy (darvadstrocel/Cx601) has regulatory approval in Europe for this indication and has been studied in multiple clinical trials. Access varies by location and clinical context.
Can stem cells help ulcerative colitis?
MSC infusion for ulcerative colitis has shown preliminary efficacy in small studies and case series. Larger randomized trials are ongoing. It is currently considered an investigational approach for UC in most clinical settings.
What are the risks of stem cell therapy for IBD?
The safety profile of MSC therapy in IBD trials has generally been favorable, with most adverse events being mild and temporary. As with any infusion-based treatment, monitoring for infusion reactions, infection risk, and immune effects is part of responsible clinical management.
How does MSC therapy differ from biologic treatments for IBD?
Biologics target specific inflammatory molecules (e.g., TNF-α, integrins, IL-12/23). MSC therapy works more broadly, modulating the overall immune environment and promoting regulatory tolerance. They may have complementary or additive effects, and some research is exploring MSC therapy in combination with biologics.
Key Takeaways
- MSC-based IBD treatment uses MSCs to modulate the dysregulated immune responses driving intestinal inflammation
- Common symptoms of inflammatory bowel disease include abdominal pain, chronic diarrhea, bleeding, and fatigue
- MSC therapy for Crohn’s fistulas has the strongest clinical evidence, including a positive Phase 3 trial
- Systemic MSC infusion for luminal Crohn’s and ulcerative colitis shows promise in Phase 2 studies
- Autologous HSCT is available for highly selected, severe, treatment-resistant Crohn’s disease
- This approach is most relevant for refractory IBD after conventional therapies have been tried
To learn more about stem cell therapy and whether it may be relevant to your gastrointestinal health, schedule a stem cell therapy consultation at Ways2Well, or schedule a consultation with our medical team to discuss your individual situation.
References
- Forbes GM, Sturm MJ, Leong RW, et al. “A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn’s disease refractory to biologic therapy.” Clin Gastroenterol Hepatol. 2014;12(1):64–71. DOI: https://doi.org/10.1016/j.cgh.2013.06.021
- Liang J, Zhang H, Wang D, et al. “Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease.” Gut. 2012;61(3):468–469. DOI: https://doi.org/10.1136/gutjnl-2011-300083
- Panés J, García-Olmo D, Van Assche G, et al. “Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial.” Lancet. 2016;388(10051):1281–1290. DOI: https://doi.org/10.1016/S0140-6736(16)31203-X31203-X)
- Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. “Ulcerative colitis.” Lancet. 2012;380(9853):1606–1619. DOI: https://doi.org/10.1016/S0140-6736(12)60150-060150-0)
Author: Ways2Well Editorial Team
Reviewed by: Scientific Advisory Board member